Durvalumab plus tremelimumab influence on response to subsequent treatments in patients with neuroendocrine neoplasms (NENs) of gastroenteropancreatic and lung origins: Results from the phase II DUNE trial (GETNE 1601)

Hernando, J.Manzano, J. L.Teule, A.Lopez, C.Garcia-Carbonero, R.Benavent Vinuales, M.Custodio, A.Cubillo, A.Alonso, V.Alonso-Gordoa, T.Carmona-Bayonas, A.Crespo, G.Blanco, M.Jimenez-Fonseca, P.Viudez, A.La Casta, A.Sevilla, I.Llanos, M.Segura, A.Capdevila, J.2025-01-072025-01-072021-09-210923-7534https://hdl.handle.net/10668/27027enDurvalumab plus tremelimumab influence on response to subsequent treatments in patients with neuroendocrine neoplasms (NENs) of gastroenteropancreatic and lung origins: Results from the phase II DUNE trial (GETNE 1601)conference outputopen access10.1016/j.annonc.2021.08.1811569-8041https://doi.org/10.1016/j.annonc.2021.08.181700527702117